{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T12:11:03Z","timestamp":1782907863342,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"funder":[{"name":"University of Bern"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Hintergrund<\/jats:title>\n                    <jats:p>Trotz geringerer Inzidenz zeigen Frauen mit Harnblasenkarzinom schlechtere \u00dcberlebensraten als M\u00e4nner. Bisherige Studien liefern jedoch nur unzureichende Daten zu geschlechtsspezifischen Therapieergebnissen, insbesondere nach radikaler Fr\u00fchzystektomie bei BCG-Versagen (Bacillus Calmette-Gu\u00e9rin).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Fragestellung<\/jats:title>\n                    <jats:p>Gibt es geschlechtsspezifische Unterschiede im onkologischen Outcome und in der Komplikationsrate nach radikaler Fr\u00fchzystektomie bei Patienten mit nicht-muskelinvasivem Harnblasenkarzinom nach Versagen der BCG-Instillationstherapie?<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material und Methoden<\/jats:title>\n                    <jats:p>Im Januar 2025 wurde eine systematische Literaturrecherche in MEDLINE und der Cochrane Library durchgef\u00fchrt. Das vollst\u00e4ndige Studienprotokoll ist prospektiv bei PROSPERO registriert (ID CRD42024611111) worden.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ergebnisse<\/jats:title>\n                    <jats:p>Drei retrospektive Kohortenstudien mit insgesamt 655\u00a0Patient*innen (davon 18,8\u202f% Frauen) wurden eingeschlossen. Es zeigten sich keine signifikanten geschlechtsspezifischen Unterschiede in Bezug auf Gesamt\u00fcberleben, krebsspezifisches \u00dcberleben oder Progression. Daten zu Komplikationen und Lebensqualit\u00e4t lagen nur begrenzt bzw. nicht vor. In 2\u00a0Studien wurde der Befall der prostatischen Urethra als negativer prognostischer Marker bei M\u00e4nnern identifiziert.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Schlussfolgerung<\/jats:title>\n                    <jats:p>Die aktuelle Evidenzlage ist sp\u00e4rlich, methodisch limitiert und durch die Unterrepr\u00e4sentation von Frauen verzerrt. Daher sind belastbare Aussagen zur Auswirkung des Geschlechts auf die Wirksamkeit der Fr\u00fchzystektomie nach BCG-Versagen nicht m\u00f6glich. Weitere Forschung zu geschlechtsabh\u00e4ngigen Risikofaktoren, insbesondere hormonellen und immunologischen Einfl\u00fcssen, ist zur Entwicklung von personalisierten Therapiestrategien dringend erforderlich.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00120-025-02665-8","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T15:06:39Z","timestamp":1754406399000},"page":"300-307","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Geschlechtsspezifische Unterschiede in Ergebnis und \u00dcberleben bei der Fr\u00fchzystektomie","Gender-specific differences in outcome and survival in early cystectomy"],"prefix":"10.1007","volume":"65","author":[{"given":"Laila","family":"Schneidewind","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Kiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Kranz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedemann","family":"Zengerling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabel","family":"Spek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemarie","family":"Uhlig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,5]]},"reference":[{"key":"2665_CR1","unstructured":"(2020) https:\/\/shorturl.at\/EcVkm"},{"key":"2665_CR2","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","volume":"63","author":"M Burger","year":"2013","unstructured":"Burger\u00a0M, Catto\u00a0JWF, Dalbagni\u00a0G, Grossman\u00a0HB, Herr\u00a0H, Karakiewicz\u00a0O et\u00a0al (2013) Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 63:234\u2013241","journal-title":"Eur Urol"},{"key":"2665_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.eururo.2011.03.047","volume":"60","author":"C Bosetti","year":"2011","unstructured":"Bosetti\u00a0C, Bertuccio\u00a0P, Chatenoud\u00a0L, Negri\u00a0E, La Veccia\u00a0C, Levi\u00a0F (2011) Trends in mortality from urologic cancers in Europe, 1970\u20132008. Eur Urol 60:1\u201315","journal-title":"Eur Urol"},{"key":"2665_CR4","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s11255-015-0980-6","volume":"47","author":"S Liu","year":"2015","unstructured":"Liu\u00a0S, Yang\u00a0T, Na\u00a0R, Hu\u00a0M, Zhang\u00a0L, Fu\u00a0Y et\u00a0al (2015) The impact of female gender on bladder cancer-specific death risk after radical cystectomy: a\u00a0meta-analysis of 27,912 patients. Int Urol Nephrol 47:951\u2013958","journal-title":"Int Urol Nephrol"},{"key":"2665_CR5","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.euf.2019.06.001","volume":"7","author":"MJ Krimphove","year":"2021","unstructured":"Krimphove\u00a0MJ, Szymaniak\u00a0J, Marchese\u00a0M, Tully\u00a0KH, D\u2019Andrea\u00a0D, Mossanen\u00a0M et\u00a0al (2021) Sex-specific Differences in the Quality of Treatment of Muscle-invasive Bladder Cancer Do Not Explain the Overall Survival Discrepancy. Eur Urol Focus 7:124\u2013131","journal-title":"Eur Urol Focus"},{"key":"2665_CR6","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1002\/cncr.28416","volume":"120","author":"JA Cohn","year":"2014","unstructured":"Cohn\u00a0JA, Vekhter\u00a0B, Lyttle\u00a0C, Steinberg\u00a0GD, Large\u00a0MC (2014) Sex disparities in diagnosis of bladder cancer after initial presentation with hematuria: a\u00a0nationwide claims-based investigation. Cancer 120:555\u2013561","journal-title":"Cancer"},{"key":"2665_CR7","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.ejca.2010.10.007","volume":"47","author":"K Dietrich","year":"2011","unstructured":"Dietrich\u00a0K, Demidenko\u00a0E, Schned\u00a0A, Zens\u00a0MS, Heaney\u00a0J, Karagas\u00a0MR (2011) Parity, early menopause and the incidence of bladder cancer in women: a\u00a0case-control study and meta-analysis. Eur J Cancer 47:592\u2013599","journal-title":"Eur J Cancer"},{"key":"2665_CR8","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/cncr.23986","volume":"115","author":"E Scosyrev","year":"2009","unstructured":"Scosyrev\u00a0E, Noyes\u00a0K, Feng\u00a0C, Messing\u00a0E (2009) Sex and racial differences in bladder cancer presentation and mortality in the US. Cancer 115:68\u201374","journal-title":"Cancer"},{"key":"2665_CR9","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.eururo.2010.01.030","volume":"57","author":"A Stenzl","year":"2010","unstructured":"Stenzl\u00a0A (2010) Words of wisdom. Re: sex and racial differences in bladder cancer presentation and mortality in the US. Eur Urol 57:729","journal-title":"Eur Urol"},{"key":"2665_CR10","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1093\/ije\/dyz264","volume":"49","author":"M Abufaraj","year":"2020","unstructured":"Abufaraj\u00a0M, Shariat\u00a0S, Moschini\u00a0M, Rohrer\u00a0F, Papantoniou\u00a0K, Devore\u00a0E et\u00a0al (2020) The impact of hormones and reproductive factors on the risk of bladder cancer in women: results from the Nurses\u2019 Health Study and Nurses\u2019 Health Study II. Int J Epidemiol 49:599\u2013607","journal-title":"Int J Epidemiol"},{"key":"2665_CR11","doi-asserted-by":"publisher","first-page":"9399","DOI":"10.1007\/s00432-023-04788-x","volume":"149","author":"L Schneidewnd","year":"2023","unstructured":"Schneidewnd\u00a0L, Kiss\u00a0B, Zengerling\u00a0F, Borkowetz\u00a0A, Graf\u00a0S, Kranz\u00a0J et\u00a0al (2023) Gender-specific outcomes in immune checkpoint inhibitor therapy for advanced or metastatic urothelial cancer: a\u00a0systematic review and meta-analysis. J\u00a0Cancer Res Clin Oncol 149:9399\u20139408","journal-title":"J Cancer Res Clin Oncol"},{"key":"2665_CR12","doi-asserted-by":"publisher","DOI":"10.1159\/000542473","author":"L Schneidewind","year":"2024","unstructured":"Schneidewind\u00a0L, Kiss\u00a0B, Kranz\u00a0J, Zengerling\u00a0F, Borkowetz\u00a0A, Graf\u00a0S et\u00a0al (2024) Gender-Specific Differences in Recurrence and Progression following Bacillus Calmette-Gu\u00e9rin Instillation for Non-Muscle-Invasive Bladder Cancer. Urol Int. https:\/\/doi.org\/10.1159\/000542473","journal-title":"Urol Int"},{"key":"2665_CR13","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00432-025-06108-x","volume":"151","author":"L Schneidewind","year":"2025","unstructured":"Schneidewind\u00a0L, Kiss\u00a0B, Neumann\u00a0T, Kranz\u00a0J, Zengerling\u00a0F, Graf\u00a0S et\u00a0al (2025) Sex-specific differences in recurrence and progression following cytostatic intravesical chemotherapy for non-muscle invasive urothelial bladder cancer (NMIBC). J\u00a0Cancer Res Clin Oncol 151:59","journal-title":"J Cancer Res Clin Oncol"},{"key":"2665_CR14","doi-asserted-by":"publisher","unstructured":"Cochrane Germany, Institut f\u00fcr Medizinische Biometrie und Statistik, Freiburg, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften \u2013 Institut f\u00fcr Medizinisches Wissensmanagement, \u00c4rztliches Zentrum f\u00fcr Qualit\u00e4t in der Medizin \u201eManual zur Bewertung des Biasrisikos in Interventionsstudien\u201c. 2.\u00a0Edition 2021. Cochrane Germany. https:\/\/www.cochrane.de\/de\/literaturbewertunghttps:\/\/doi.org\/10.6094\/UNIFR\/194900","DOI":"10.6094\/UNIFR\/194900"},{"key":"2665_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2016.01.087","author":"CR Haas","year":"2016","unstructured":"Haas\u00a0CR, Barlow\u00a0LJ, Badalato\u00a0GM, DeCastro\u00a0DJ, Benson\u00a0MC, McKiernan\u00a0JM (2016) The Timing of Radical Cystectomy for BCG Failure: Comparison of Outcomes and Risk Factors for Prognosis. J\u00a0Urol. https:\/\/doi.org\/10.1016\/j.juro.2016.01.087","journal-title":"J Urol"},{"key":"2665_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2010.03.134","author":"DC Chade","year":"2010","unstructured":"Chade\u00a0DC, Shariat\u00a0SF, Adami\u00a0A, Bochner\u00a0BH, Donat\u00a0SM, Herr\u00a0HW et\u00a0al (2010) Clinical Outcome of Primary Versus Secondary Bladder Carcinoma In Situ. J\u00a0Urol. https:\/\/doi.org\/10.1016\/j.juro.2010.03.134","journal-title":"J Urol"},{"key":"2665_CR17","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.eururo.2005.03.021","volume":"48","author":"J Huguet","year":"2005","unstructured":"Huguet\u00a0J, Crego\u00a0M, Sabate\u00a0S, Salvador\u00a0J, Palou\u00a0J, Villavincencio\u00a0H (2005) Cystectomy in Patients with High Risk Superficial Bladder Tumors Who Fail Intravesical BCG Therapy: Pre-Cystectomy Prostate Involvement as a\u00a0Prognostic Factor. Eur Urol 48:53\u201359","journal-title":"Eur Urol"},{"key":"2665_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2020.08.004","author":"KH Tully","year":"2020","unstructured":"Tully\u00a0KH, Cole\u00a0AP, Krimphove\u00a0MJ, Friedlander\u00a0DF, Mossanen\u00a0M, Herzog\u00a0P et\u00a0al (2020) Contemporary Treatment Patterns for Non-muscle-invasive Bladder Cancer: Has the Use of Radical Cystectom Changed in the BCG Shortage Era? Urology. https:\/\/doi.org\/10.1016\/j.urology.2020.08.004","journal-title":"Urology"},{"key":"2665_CR19","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41568-024-00772-w","volume":"25","author":"GP Dotto","year":"2025","unstructured":"Dotto\u00a0GP, Buckinx\u00a0A, \u00d6zdemir\u00a0BC, Simon\u00a0C (2025) Androgen receptor signaling in non-prostatic malignancies: challenges and opportunities. Nat Rev Cancer 25:93\u2013108","journal-title":"Nat Rev Cancer"},{"key":"2665_CR20","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/imm.12013","volume":"137","author":"S Bodhankar","year":"2012","unstructured":"Bodhankar\u00a0S, Vandenbark\u00a0AA, Offner\u00a0H (2012) Oestrogen treatment of experimental autoimmune encephalomyelitis requires 17\u03b2-oestradiol-receptor-positive B\u00a0cells that up-regulate PD\u20111 on CD4+ Foxp3+ regulatory T\u00a0cells. Immunology 137:282\u2013293","journal-title":"Immunology"},{"key":"2665_CR21","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1002\/eji.201040992","volume":"41","author":"S Bodhankar","year":"2011","unstructured":"Bodhankar\u00a0S, Wang\u00a0C, Vandenbark\u00a0AA, Offner\u00a0H (2011) Estrogen-induced protection against experimental autoimmune encephalomyelitis is abrogated in the absence of B\u00a0cells. Eur J Immunol 41:1165\u20131175","journal-title":"Eur J Immunol"},{"key":"2665_CR22","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.euros.2021.05.002","volume":"29","author":"S Chenard","year":"2021","unstructured":"Chenard\u00a0S, Jackson\u00a0C, Vidotto\u00a0T, Chen\u00a0L, Hardy\u00a0C, Jamaspishvilli\u00a0T, Berman\u00a0D, Siemens\u00a0DR, Koti\u00a0M (2021) Sexual Dimorphism in Outcomes of Non-muscle-invasive Bladder Cancer: A\u00a0Role of CD163+ Macrophages, B\u00a0cells, and PD-L1 Immune Checkpoint. Eur Urol Open Sci 29:50\u201358","journal-title":"Eur Urol Open Sci"},{"key":"2665_CR23","doi-asserted-by":"publisher","first-page":"172","DOI":"10.3389\/fimmu.2017.00172","volume":"8","author":"RM Guzman-Genuino","year":"2017","unstructured":"Guzman-Genuino\u00a0RM, Diener\u00a0KR (2017) Regulatory B Cells in Pregnancy: Lessons from Autoimmunity, Graft Tolerance, and Cancer. Front Immunol 8:172","journal-title":"Front Immunol"},{"key":"2665_CR24","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.molimm.2016.07.015","volume":"77","author":"BG Jones","year":"2016","unstructured":"Jones\u00a0BG, Penkert\u00a0RR, Xu\u00a0B, Fan\u00a0Y, Neale\u00a0G, Gearhart\u00a0PJ, Hurwitz\u00a0JL (2016) Binding of estrogen receptors to switch sites and regulatory elements in the immunoglobulin heavy chain locus of activated B\u00a0cells suggests a\u00a0direct influence of estrogen on antibody expression. Mol Immunol 77:97\u2013102","journal-title":"Mol Immunol"},{"key":"2665_CR25","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1093\/intimm\/dxy074","volume":"31","author":"BG Jones","year":"2019","unstructured":"Jones\u00a0BG, Sealy\u00a0RE, Penkert\u00a0RR, Surman\u00a0SL, Maul\u00a0RW, Neale\u00a0G, Xu\u00a0B, Gearhart\u00a0PJ, Hurwitz\u00a0JL (2019) Complex sex-biased antibody responses: estrogen receptors bind estrogen response elements centered within immunoglobulin heavy chain gene enhancers. Int Immunol 31:141\u2013156","journal-title":"Int Immunol"},{"key":"2665_CR26","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/cmi.2017.35","volume":"14","author":"A Sarvaria","year":"2017","unstructured":"Sarvaria\u00a0A, Madrigal\u00a0JA, Saudemont\u00a0A (2017) B\u00a0cell regulation in cancer and anti-tumor immunity. Cell Mol Immunol 14:662\u2013674","journal-title":"Cell Mol Immunol"},{"key":"2665_CR27","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13293-025-00715-6","volume":"16","author":"P Chaudhary","year":"2025","unstructured":"Chaudhary\u00a0P, Singha\u00a0B, Abdel-Hafiz\u00a0HA, Velegraki\u00a0M, Sundi\u00a0D, Satturwa\u00a0S et\u00a0al (2025) Sex differences in bladder cancer: understanding biological and clinical implications. Biol Sex Differ 16:31","journal-title":"Biol Sex Differ"},{"key":"2665_CR28","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s00120-025-02557-x","volume":"64","author":"L Schneidewind","year":"2025","unstructured":"Schneidewind\u00a0L, Sommerhalder\u00a0B, Willi\u00a0D, R\u00f6nnau\u00a0C, Uhlig\u00a0A, Kiss\u00a0B (2025) Association of glitazones and bladder cancer: a\u00a0rapid review. Urologie 64:669\u2013667","journal-title":"Urologie"},{"key":"2665_CR29","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.euo.2024.03.014","volume":"7","author":"C Cerrato","year":"2024","unstructured":"Cerrato\u00a0C, Crocerossa\u00a0F, Marchioni\u00a0M, Giannarini\u00a0G, Gupta\u00a0S, Albiges\u00a0L et\u00a0al (2024) Effect of Sex on the Oncological Outcomes in Response to Immunotherapy and Antibody-drug Conjugates in Patients with Urothelial and Kidney Cancer: A\u00a0Systematic Review and a\u00a0Network Meta-analysis. Eur Urol Oncol 7:1005\u20131014","journal-title":"Eur Urol Oncol"},{"key":"2665_CR30","doi-asserted-by":"publisher","DOI":"10.1097\/01.JU.0001111604.90306.91.05","author":"JL Gore","year":"2025","unstructured":"Gore\u00a0JL, Wolff\u00a0EM, Nash\u00a0MG, Comstock\u00a0BA, Gilbert\u00a0SM, Wright\u00a0JL et\u00a0al (2025) Radical cystectomy versus bladder-sparing therapy for recurrent high-grade non-muscle invasive bladder cancer: Results from the comparison of intravesical therapy and surgery as treatment options (CISTO) study. J\u00a0Urol. https:\/\/doi.org\/10.1097\/01.JU.0001111604.90306.91.05 (Abstract)","journal-title":"J Urol"}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-025-02665-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-025-02665-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-025-02665-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T12:50:35Z","timestamp":1773233435000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-025-02665-8"}},"subtitle":["Eine systematische \u00dcbersichtsarbeit","Systematic review"],"short-title":[],"issued":{"date-parts":[[2025,8,5]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["2665"],"URL":"https:\/\/doi.org\/10.1007\/s00120-025-02665-8","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"value":"2731-7064","type":"print"},{"value":"2731-7072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,5]]},"assertion":[{"value":"15 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"L.\u00a0Schneidewind, B.\u00a0Kiss, N.\u00a0Arnold, J.\u00a0Kranz, F.\u00a0Zengerling, A.\u00a0Spek, T.\u00a0Neumann und A.\u00a0Uhlig geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}